Navigation Links
HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
Date:3/12/2009

The HemAway Seat(R) offers relief for sufferers of prolapsed internal hemorrhoids

BERKELEY HEIGHTS, N.J., March 12 /PRNewswire/ -- HemAway(R) (www.HemAway.com) announced today the launch of its first FDA-cleared consumer product, the HemAway Seat(R), a painless, non-invasive, discreet, and easy-to-use hemorrhoid treatment device that alleviate the discomfort and agony of prolapsed internal hemorrhoids within minutes of use.

Fitted for seamless and discreet installation on most toilet models, the HemAway Seat naturally uses one's body weight to allow the prolapsed internal hemorrhoid to gently withdraw back into the body, relieving pain, discomfort, and irritation.

HemAway is the brainchild of founder and developer Dr. John Maurello, a practicing chiropractor and long-time sufferer of internal hemorrhoids that would not respond to available treatments and surgery. He created the HemAway Seat upon making a life-changing discovery that eliminated the discomfort of his debilitating condition and allowed him to reclaim his quality of life. "Once I realized its efficacy, I knew the seat would prove to be a welcomed relief for the millions of hemorrhoid sufferers seeking a simple, painless, effective solution to help heal and manage their condition," states Dr. Maurello.

The HemAway Seat fills an urgent need for millions of sufferers who seek alternatives to the few available treatments for internal hemorrhoids. Hemorrhoid creams and home remedies are marginally helpful and at best reduce swelling or mask the pain of the condition. Invasive procedures are the only other available therapies and force patients to face the risks of hemorrhoid surgeries such as permanent incontinence. Dr. Maurello adds, "There is a void for effective treatments that are non-invasive and risk-free."

Approximately half of all Americans experience hemorrhoids by the age of 50 [source: NIH] and 70 percent of women suffer from hemorrhoids at some point during pregnancy or after delivery. [source: Francis-Cheung, Theresa. Pregnancy Weight Management. Adams Media, 2000, p.124.] According to one clinical study, 41 percent of advanced-stage hemorrhoid sufferers were unsatisfied with the results of surgical removal. [source: Surg Endosc. 2008 Nov; 22(11):2379-83. Epub 2008 Jul 12.] These hemorrhoid statistics clearly indicate the need for a product like the HemAway Seat that effectively treats chronic hemorrhoids so that drastic and painful invasive procedures can be avoided and helps sufferers manage the condition when surgical treatments fail.

The HemAway Seat is available for purchase at HemAway.com in both home ($199) and travel models ($129).

About HemAway

Founded by serial entrepreneurs and seasoned medical professionals in 2007, HemAway(R) is a medical device company based in Berkeley Heights, NJ with a mission to develop and market innovative products to meet common medical problems. In early 2009, HemAway launched its first consumer product, the HemAway Seat(R). Cleared for marketing by the FDA, the HemAway Seat was developed specifically to bring relief to the sufferers of prolapsed internal hemorrhoids. HemAway supports American businesses by insuring all products are designed and manufactured in the US. For more information, visit www.HemAway.com.

    CONTACT: Esther Koo, Southard Communications
    212.777.2220/esther@southardinc.com


'/>"/>
SOURCE HemAway
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: